The World Health Organization HIV Drug Resistance Prevention and Assessment Strategy

The World Health Organization HIV Drug Resistance Prevention and Assessment Strategy PDF Author: Michael R. Jordan
Publisher:
ISBN:
Category :
Languages : en
Pages : 136

Get Book Here

Book Description

The World Health Organization HIV Drug Resistance Prevention and Assessment Strategy

The World Health Organization HIV Drug Resistance Prevention and Assessment Strategy PDF Author: Michael R. Jordan
Publisher:
ISBN:
Category :
Languages : en
Pages : 136

Get Book Here

Book Description


Implementation of the World Health Organization's Strategy for HIV Drug Resistance Prevention and Assessment in Countries Scaling Up Antiretroviral Treatment

Implementation of the World Health Organization's Strategy for HIV Drug Resistance Prevention and Assessment in Countries Scaling Up Antiretroviral Treatment PDF Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 121

Get Book Here

Book Description


HIV drug resistance strategy, 2021 update

HIV drug resistance strategy, 2021 update PDF Author:
Publisher: World Health Organization
ISBN: 9240030565
Category : Medical
Languages : en
Pages : 36

Get Book Here

Book Description


Report on the global action plan on HIV drug resistance 2017–2021

Report on the global action plan on HIV drug resistance 2017–2021 PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240071083
Category : Medical
Languages : en
Pages : 40

Get Book Here

Book Description


Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection PDF Author: World Health Organization
Publisher:
ISBN: 9789241549684
Category : AIDS (Disease)
Languages : en
Pages : 429

Get Book Here

Book Description
These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care. This edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.

HIV drug resistance

HIV drug resistance PDF Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240086315
Category : Medical
Languages : en
Pages : 46

Get Book Here

Book Description
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment. In this report, WHO documents high levels of HIV viral load suppression (>90%) in populations receiving dolutegravir (DTG)-containing antiretroviral therapy (ART). However, recent observational data reveal that HIVDR to DTG is emerging at levels exceeding those observed in clinical trials. Few countries have reported people not achieving viral suppression while receiving DTG-containing ART. However, amongst the surveys reported, levels of DTG resistance ranged from 3.9% to 8.6%, with levels as high as 19.6% observed among highly treatment-experienced people who transitioned to a DTG-containing ART while having high HIV viral loads. Levels of observed DTG resistance in real world populations receiving ART appear to be higher than anticipated from clinical trials. WHO recommends that countries routinely implement standardised surveillance of HIVDR to follow the prevalence and patterns of resistance among people not achieving suppressed viral load. The use of long acting cabotegravir (CAB-LA) for pre-exposure prophylaxis (PrEP) greatly reduces the risk of acquiring HIV. However, INSTI resistance has been observed in some cases with recent CAB-LA exposure, and delayed detection and confirmation of HIV infection can increase the risk of selection of INSTI drug resistance–associated mutations. Despite the possible risk, the roll-out of CAB-LA for PrEP should not be hindered. Scale-up of PrEP should be accompanied by standardized surveillance of drug resistance among people testing positive for HIV while receiving PrEP.

WORLD HEALTH ORGANIZATION GLOBAL STRATEGY FOR THE SURVEILLANCE AND MONITORING OF HIV DRUG RESISTANCE.

WORLD HEALTH ORGANIZATION GLOBAL STRATEGY FOR THE SURVEILLANCE AND MONITORING OF HIV DRUG RESISTANCE. PDF Author: world health organization
Publisher:
ISBN:
Category :
Languages : en
Pages : 0

Get Book Here

Book Description


TB/HIV

TB/HIV PDF Author: A. D. Harries
Publisher: World Health Organization
ISBN: 9241546344
Category : Medical
Languages : en
Pages : 213

Get Book Here

Book Description
This manual is designed for health professionals working in high HIV and TB prevalence countries. It summarises the characteristics of both diseases and their interactions. It concentrates particularly on the problems of diagnosis and management both in adults and children and summarises the other HIV related illnesses the clinician might encounter.

HIV DRUG RESISTANCE STRATEGY: 2021 UPDATE.

HIV DRUG RESISTANCE STRATEGY: 2021 UPDATE. PDF Author: world health organization
Publisher:
ISBN:
Category :
Languages : en
Pages : 0

Get Book Here

Book Description


MEETING REPORT ON ASSESSMENT OF WORLD HEALTH ORGANIZATION HIV DRUG RESISTANCE EARLY WARNING INDICATORS: Report of the Early Warning Indicator Advisory Panel Meeting

MEETING REPORT ON ASSESSMENT OF WORLD HEALTH ORGANIZATION HIV DRUG RESISTANCE EARLY WARNING INDICATORS: Report of the Early Warning Indicator Advisory Panel Meeting PDF Author: world health organization
Publisher:
ISBN:
Category :
Languages : en
Pages : 0

Get Book Here

Book Description